Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

ClinicalTrials.gov ID: NCT00309699

Public ClinicalTrials.gov record NCT00309699. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared With Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes in Bipolar Disorder

Study identification

NCT ID
NCT00309699
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Enrollment
493 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Quetiapine Drug
  • Paliperidone ER Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2006
Primary completion
Aug 31, 2007
Completion
Oct 31, 2007
Last update posted
Jun 19, 2014

2006 – 2007

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
22
Facility City State ZIP Site status
Not listed Cerritos California
Not listed Garden Grove California
Not listed Oceanside California
Not listed San Diego California
Not listed Bradenton Florida
Not listed Fort Lauderdale Florida
Not listed Kissimmee Florida
Not listed Maitland Florida
Not listed South Miami Florida
Not listed Tampa Florida
Not listed Chicago Illinois
Not listed Indianapolis Indiana
Not listed Prairie Village Kansas
Not listed Lake Charles Louisiana
Not listed Shreveport Louisiana
Not listed Flowood Mississippi
Not listed Clementon New Jersey
Not listed Moore Oklahoma
Not listed Oklahoma City Oklahoma
Not listed Philadelphia Pennsylvania
Not listed Memphis Tennessee
Not listed Dallas Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00309699, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 19, 2014 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00309699 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →